HER2 dendritic cell vaccine

The HER2 dendritic cell vaccine is an investigational immunotherapy designed to stimulate the immune system to recognize and attack cancer cells that overexpress the human epidermal growth factor receptor 2 (HER2). The therapy involves extracting a patient's own dendritic cells and exposing them ex vivo to fragments or peptides of the HER2 protein. These "trained" antigen-presenting cells are then reintroduced into the patient—often directly into tumor tissue—to activate T-cell responses specifically against HER2-expressing tumor cells. The mechanism of action centers on enhancing anti-tumor immunity by promoting both antibody-mediated and T-cell–mediated responses targeting the HER2 antigen. Clinical studies have shown promising results in patients with early-stage or locally advanced (stage II/III) breast cancer that is positive for HER2 expression, particularly in estrogen receptor-negative subtypes. The approach has demonstrated safety, immunogenicity, and preliminary clinical benefit as monotherapy or in combination with chemotherapy[6][8][5][3][4].

Other names

HER2-directed dendritic cell vaccineHER-2-directed dendritic cell vaccineHER 2-directed dendritic cell vaccineHER-2 pulsed dendritic cell vaccineHER2 pulsed dendritic cell vaccineHER 2 pulsed dendritic cell vaccine